Role of antiidiotypic antibodies on the clinical course of idiopathic thrombocytopenic purpura

Y. S. Mehta, K. Ghosh, S. S. Badakere, A. V. Pathare, Dipika Mohanty

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The severity and clinical course of idiopathic thrombocytopenic purpura (ITP) vary from patient to patient. The factors responsible for this variation are not well understood. In this study we attempted to evaluate the role of antiidiotypic antibodies in the immunoregulation of the disease. We investigated 114 cases of chronic ITP in adults. We determined antiidiotypic antibodies against antiplatelet antibodies using (a) idiotype-binding enzyme-linked immunosorbent assay (ELISA), (b) paratope-blocking ELISA, and (c) Western blotting. Results indicated that 80.6%, 11.2%, and 8.3% of the patients, respectively, presented with antiidiotypes against antibodies to GPIIb/IIIa, GPIb/IX, and both GPIIb/IIIa and GPIb/IX. More than 70% of the patients who showed high levels of blocking of antiidiotypic antibodies went into complete remission, compared with less than 5% of patients who showed low levels of such antibodies (P <.01). Disease severity was also found to be inversely related (P <0.01) to the degree of blocking of antiidiotypic antibodies. The results of this study suggest that antiidiotypic antibodies against antiplatelet antibodies are a potential prognostic marker in chronic ITP.

Original languageEnglish
Pages (from-to)113-120
Number of pages8
JournalJournal of Laboratory and Clinical Medicine
Volume142
Issue number2
DOIs
Publication statusPublished - Aug 1 2003
Externally publishedYes

Fingerprint

Idiopathic Thrombocytopenic Purpura
Antibodies
Immunosorbents
Blocking Antibodies
Assays
Enzyme-Linked Immunosorbent Assay
Antibody Binding Sites
Enzymes
Western Blotting

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Role of antiidiotypic antibodies on the clinical course of idiopathic thrombocytopenic purpura. / Mehta, Y. S.; Ghosh, K.; Badakere, S. S.; Pathare, A. V.; Mohanty, Dipika.

In: Journal of Laboratory and Clinical Medicine, Vol. 142, No. 2, 01.08.2003, p. 113-120.

Research output: Contribution to journalArticle

Mehta, Y. S. ; Ghosh, K. ; Badakere, S. S. ; Pathare, A. V. ; Mohanty, Dipika. / Role of antiidiotypic antibodies on the clinical course of idiopathic thrombocytopenic purpura. In: Journal of Laboratory and Clinical Medicine. 2003 ; Vol. 142, No. 2. pp. 113-120.
@article{aa998a96e8e34ee8aab11bf8f4296fa6,
title = "Role of antiidiotypic antibodies on the clinical course of idiopathic thrombocytopenic purpura",
abstract = "The severity and clinical course of idiopathic thrombocytopenic purpura (ITP) vary from patient to patient. The factors responsible for this variation are not well understood. In this study we attempted to evaluate the role of antiidiotypic antibodies in the immunoregulation of the disease. We investigated 114 cases of chronic ITP in adults. We determined antiidiotypic antibodies against antiplatelet antibodies using (a) idiotype-binding enzyme-linked immunosorbent assay (ELISA), (b) paratope-blocking ELISA, and (c) Western blotting. Results indicated that 80.6{\%}, 11.2{\%}, and 8.3{\%} of the patients, respectively, presented with antiidiotypes against antibodies to GPIIb/IIIa, GPIb/IX, and both GPIIb/IIIa and GPIb/IX. More than 70{\%} of the patients who showed high levels of blocking of antiidiotypic antibodies went into complete remission, compared with less than 5{\%} of patients who showed low levels of such antibodies (P <.01). Disease severity was also found to be inversely related (P <0.01) to the degree of blocking of antiidiotypic antibodies. The results of this study suggest that antiidiotypic antibodies against antiplatelet antibodies are a potential prognostic marker in chronic ITP.",
author = "Mehta, {Y. S.} and K. Ghosh and Badakere, {S. S.} and Pathare, {A. V.} and Dipika Mohanty",
year = "2003",
month = "8",
day = "1",
doi = "10.1016/S0022-2143(03)00104-5",
language = "English",
volume = "142",
pages = "113--120",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Role of antiidiotypic antibodies on the clinical course of idiopathic thrombocytopenic purpura

AU - Mehta, Y. S.

AU - Ghosh, K.

AU - Badakere, S. S.

AU - Pathare, A. V.

AU - Mohanty, Dipika

PY - 2003/8/1

Y1 - 2003/8/1

N2 - The severity and clinical course of idiopathic thrombocytopenic purpura (ITP) vary from patient to patient. The factors responsible for this variation are not well understood. In this study we attempted to evaluate the role of antiidiotypic antibodies in the immunoregulation of the disease. We investigated 114 cases of chronic ITP in adults. We determined antiidiotypic antibodies against antiplatelet antibodies using (a) idiotype-binding enzyme-linked immunosorbent assay (ELISA), (b) paratope-blocking ELISA, and (c) Western blotting. Results indicated that 80.6%, 11.2%, and 8.3% of the patients, respectively, presented with antiidiotypes against antibodies to GPIIb/IIIa, GPIb/IX, and both GPIIb/IIIa and GPIb/IX. More than 70% of the patients who showed high levels of blocking of antiidiotypic antibodies went into complete remission, compared with less than 5% of patients who showed low levels of such antibodies (P <.01). Disease severity was also found to be inversely related (P <0.01) to the degree of blocking of antiidiotypic antibodies. The results of this study suggest that antiidiotypic antibodies against antiplatelet antibodies are a potential prognostic marker in chronic ITP.

AB - The severity and clinical course of idiopathic thrombocytopenic purpura (ITP) vary from patient to patient. The factors responsible for this variation are not well understood. In this study we attempted to evaluate the role of antiidiotypic antibodies in the immunoregulation of the disease. We investigated 114 cases of chronic ITP in adults. We determined antiidiotypic antibodies against antiplatelet antibodies using (a) idiotype-binding enzyme-linked immunosorbent assay (ELISA), (b) paratope-blocking ELISA, and (c) Western blotting. Results indicated that 80.6%, 11.2%, and 8.3% of the patients, respectively, presented with antiidiotypes against antibodies to GPIIb/IIIa, GPIb/IX, and both GPIIb/IIIa and GPIb/IX. More than 70% of the patients who showed high levels of blocking of antiidiotypic antibodies went into complete remission, compared with less than 5% of patients who showed low levels of such antibodies (P <.01). Disease severity was also found to be inversely related (P <0.01) to the degree of blocking of antiidiotypic antibodies. The results of this study suggest that antiidiotypic antibodies against antiplatelet antibodies are a potential prognostic marker in chronic ITP.

UR - http://www.scopus.com/inward/record.url?scp=0141853836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141853836&partnerID=8YFLogxK

U2 - 10.1016/S0022-2143(03)00104-5

DO - 10.1016/S0022-2143(03)00104-5

M3 - Article

C2 - 12960958

AN - SCOPUS:0141853836

VL - 142

SP - 113

EP - 120

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 2

ER -